Abstract
Autologous dendritic-cell vaccine therapy combined with systemic therapy may be of benefit in patients with metastatic renal cell cancer undergoing cytoreductive nephrectomy according to results from the large ADAPT trial. Combined retrospective analysis and correlative immunology research revealed that patients receiving everolimus may have derived a greater benefit. The currently enrolling phase 2 CoImmune trial is designed to test this hypothesis in patients undergoing cytoreductive nephrectomy and systemic therapy.
Original language | English |
---|---|
Pages (from-to) | 651-653 |
Number of pages | 3 |
Journal | European Urology Focus |
Volume | 8 |
Issue number | 3 |
DOIs | |
State | Published - May 2022 |
Keywords
- Carcinoma, Renal Cell/drug therapy
- Humans
- Immunotherapy, Active
- Kidney Neoplasms/drug therapy
- Nephrectomy/methods
- Retrospective Studies